|
C3ORF31 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62481139653892E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.70894418008538E-14 |
| Normal-vs-Stage2 |
2.32399999244848E-09 |
| Normal-vs-Stage3 |
2.57904808620424E-13 |
| Normal-vs-Stage4 |
5.14355225078589E-12 |
| Stage1-vs-Stage2 |
4.713600E-01 |
| Stage1-vs-Stage3 |
7.358500E-02 |
| Stage1-vs-Stage4 |
2.112000E-01 |
| Stage2-vs-Stage3 |
6.086400E-01 |
| Stage2-vs-Stage4 |
7.179800E-01 |
| Stage3-vs-Stage4 |
8.856200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
1.52200000003155E-06 |
| Normal-vs-Asian |
4.78020000005408E-06 |
| Caucasian-vs-AfricanAmerican |
4.297600E-01 |
| Caucasian-vs-Asian |
7.575900E-03 |
| AfricanAmerican-vs-Asian |
2.719800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.82551759767102E-13 |
| Normal-vs-Female |
1.62636570877339E-12 |
| Male-vs-Female |
9.217000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.37554420579045E-12 |
| Normal-vs-Age(41-60Yrs) |
1.64246394263046E-12 |
| Normal-vs-Age(61-80Yrs) |
1.62903024403249E-12 |
| Normal-vs-Age(81-100Yrs) |
1.220970E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.120620E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.355500E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
5.703000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
5.249400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.973400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.035200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
9.571600E-02 |
| Classical-VS-Follicular |
1.623050E-01 |
| Classical-VS-Other |
9.996000E-01 |
| Classical-VS-Normal |
1.65134572682746E-12 |
| Tall-VS-Follicular |
6.127000E-01 |
| Tall-VS-Other |
4.552000E-01 |
| Tall-VS-Normal |
8.20080003904877E-10 |
| Follicular-VS-Other |
6.677200E-01 |
| Follicular-VS-Normal |
1.67239999626645E-10 |
| Other-VS-Normal |
5.741900E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.67466041034459E-12 |
| Normal-vs-N1 |
1.82059922693156E-11 |
| N0-vs-N1 |
3.472400E-01 |
|
|
